|Systematic (IUPAC) name|
|ATC code||R03DX07 (WHO)|
|Molar mass||403.207 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Roflumilast (trade name Daxas) is a drug which acts as a selective, long-acting inhibitor of the enzyme PDE-4. It has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease (COPD). While roflumilast was found to be effective in clinical trials, it produced several dose-limiting side effects including nausea, diarrhoea and headache, and development is continuing in an attempt to minimise the incidence of side effects while retaining clinical efficacy.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|45px||This drug article relating to the respiratory system is a stub. You can help ssf by expanding it.|
- Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(2):121-9. PMID 18044684
- Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Foster PS, Kumar RK. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Clinical and Experimental Allergy. 2008 May;38(5):847-56. PMID 18307529
- Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D, Krug N, Hermann R. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulmonary Pharmacology and Therapeutics. 2008 Aug;21(4):616-23. PMID 18374614
- Field SK. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma. Expert Opinion on Investigational Drugs. 2008 May;17(5):811-8. PMID 18447606
- Spina D. PDE4 inhibitors: current status. British Journal of Pharmacology. 2008 Jul 28. PMID 18660825
- Amschler, H.; 1998, U.S. Patent 5,712,298.